A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Authors:
Open Access
- 5 August 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (19) , 4232-4239
Abstract
Purpose: To compare the efficacy and safety of high-dose vitamin C plus FOLFOX ± bevacizumab versus FOLFOX ± bevacizumab as first-line treatment in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Between 2017 and 2019, histologically confirmed patients with mCRC (n = 442) with normal glucose-6-phosphate dehydrogenase status and no prior treatment for metastatic disease were randomized (1:1) into a control (FOLFOX ± bevacizumab) and an experimental [high-dose vitamin C (1.5 g/kg/d, intravenously for 3 hours from D1 to D3) plus FOLFOX ± bevacizumab] group. Randomization was based on the primary tumor location and bevacizumab prescription. Results: The progression-free survival (PFS) of the experimental group was not superior to the control group [median PFS, 8.6 vs. 8.3 months; HR, 0.86; 95% confidence interval (CI), 0.70–1.05; P = 0.1]. The objective response rate (ORR) and overall survival (OS) of the experimental and control groups were similar (ORR, 44.3% vs. 42.1%; P = 0.9; median OS, 20.7 vs. 19.7 months; P = 0.7). Grade 3 or higher treatment-related adverse events occurred in 33.5% and 30.3% of patients in the experimental and control groups, respectively. In prespecified subgroup analyses, patients with RAS mutation had significantly longer PFS (median PFS, 9.2 vs. 7.8 months; HR, 0.67; 95% CI, 0.50–0.91; P = 0.01) with vitamin C added to chemotherapy than with chemotherapy only. Conclusions: High-dose vitamin C plus chemotherapy failed to show superior PFS compared with chemotherapy in patients with mCRC as first-line treatment but may be beneficial in patients with mCRC harboring RAS mutation.Keywords
All Related Versions
Funding Information
- Sun Yat-sen University Clinical Research (2018014)
- National Natural Science Foundation of China (81930065, 82173128)
- Science and Technology Program of Guangdong (2019B020227002)
- Science and Technology Program of Guangzhou (201904020046)
This publication has 26 references indexed in Scilit:
- Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancerCancer Chemotherapy and Pharmacology, 2013
- Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effectsFree Radical Biology and Medicine, 2009
- Phase I clinical trial of i.v. ascorbic acid in advanced malignancyAnnals of Oncology, 2008
- Analyzing survival curves at a fixed point in timeStatistics in Medicine, 2007
- Vitamins C and K3 Sensitize Human Urothelial Tumors to GemcitabineJournal of Urology, 2006
- Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitroCancer Letters, 1996
- High-Dose Vitamin C versus Placebo in the Treatment of Patients with Advanced Cancer Who Have Had No Prior ChemotherapyNew England Journal of Medicine, 1985
- Vitamin C preferential toxicity for malignant melanoma cellsNature, 1980
- Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancerProceedings of the National Academy of Sciences, 1978
- Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer.Proceedings of the National Academy of Sciences, 1976